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A 43-year-old male trisomic patient was referred for 
acute left headache and progressive homolateral my-
driasis and ptosis. Computed tomography and T2-mag-
netic resonance imaging demonstrated a 4 cm invasive 
pituitary adenoma (Panels A and C, respectively). Blood 
analyses revealed hyperprolactinemia (5460 ng/ml, 
normal values < 15 ng/ml) and severe gonadotrophic 
insufﬁ ciency. Treatment was classically initiated with a 
dopamine agonist (cabergoline, 0.5 mg per week) and 
resulted in a rapid improvement of neurological symp-
toms and prolactinemia (2247 ng/ml) (1). Three weeks 
later, the patient complained of headache, nausea and 
dizziness. Similar radiological investigations showed a 
signiﬁ cant shrinkage of macroprolactinoma, as well as 
pneumocephalus (Panels B and D, arrowheads). Cab-
ergoline treatment was continued and transnasal sur-
gery performed to seal sinus breach of the sella turcica. 
Pneumocephalus represents a severe complication of 
dopamine agonist treatment of invasive prolactinoma 
(2). Drug-induced tumour shrinkage unmasks the ero-
sion of the sella ﬂ oor, thereby allowing CSF-leakage 
and/or pneumocephalus (3).
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